CompletedPhase 2NCT02781311
A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
Studying Alopecia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Allergan
- Principal Investigator
- Joan-En LinAllergan
- Intervention
- Setipiprant(drug)
- Enrollment
- 169 enrolled
- Eligibility
- 18-49 years · MALE
- Timeline
- 2016 – 2018
Study locations (18)
- Burke Pharmaceutical Research, Hot Springs, Arkansas, United States
- Petrus Center for Aesthetic Surgery & Hair Transplantation, Little Rock, Arkansas, United States
- Therapeutics Clinical Research, San Diego, California, United States
- Radiant Research, Inc., Santa Rosa, California, United States
- DeNova Research, Chicago, Illinois, United States
- Heartland Research Associates, LLC, Wichita, Kansas, United States
- Michigan Center for Skin Care Research, Clinton Township, Michigan, United States
- Minnesota Clinical Study Center, Fridley, Minnesota, United States
- University of Minnesota Department of Dermatology Division of Clinical research, Minneapolis, Minnesota, United States
- Wake Forest University Health Sciences Department of Dermatology Medical Center Boulevard, Winston-Salem, North Carolina, United States
- Cleveland Clinic, Dept of Dermatology, Cleveland, Ohio, United States
- NW Dermatology and Research Center, Portland, Oregon, United States
- Oregon Medical Research Center, Portland, Oregon, United States
- Penn State Hershey Medical Center Dermatology Research Office, Hershey, Pennsylvania, United States
- Radiant Research, Inc., Greer, South Carolina, United States
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02781311 on ClinicalTrials.govOther trials for Alopecia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07487948Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen PlanopilarisIcahn School of Medicine at Mount Sinai
- RECRUITINGPHASE2NCT07533006A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)Eli Lilly and Company
- ENROLLING BY INVITATIONNCT07499713Association of Serum VEGF-A and VCAM-1 Levels With Nailfold Capilleroscopic Alterations in Alopecia AreataIstanbul Training and Research Hospital
- RECRUITINGPHASE3NCT07435012Androgenic Alopecia TH07 Clinical TrialTriple Hair Inc
- RECRUITINGNANCT07422376Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and Hair Regrowth in the Appalachian Highlands RegionCharles Mays
- RECRUITINGNCT07226531Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the USPfizer
- RECRUITINGNANCT07563036JAK2 Expression in Androgenetic Alopecia Before and After Topical MinoxidilKasr El Aini Hospital
- RECRUITINGPHASE2NCT07370519Topical Application of Lactobacillus Reuteri for Androgenetic AlopeciaShenzhen People's Hospital